ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
November 11, 2019 03:21 ET
|
ASLAN PHARMACEUTICALS LIMITED
- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the control...
ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
October 31, 2019 03:37 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
October 18, 2019 03:35 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secured a US$3...
New Data Presented on ASLAN’s varlitinib at ESMO 2019
October 02, 2019 02:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...
ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO
September 19, 2019 03:50 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...
Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019
September 10, 2019 05:14 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting
August 27, 2019 06:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 13, 2019 04:03 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer
May 10, 2019 04:15 ET
|
ASLAN Pharmaceuticals Limited
- K-MASTER, Korea’s leading precision medicine research group, to conduct phase 1b/2 umbrella study testing varlitinib as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic...
ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
February 26, 2019 17:35 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...